A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (deudextromethorphan Hydrobromide [d6-DM]/quinidine Sulfate [Q]) for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type

This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.

开始日期2020-09-03

申办/合作机构

Otsuka Pharmaceutical Development & Commercialization, Inc.

NCT04408755 / Active, not recruiting临床3期

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

开始日期2020-07-08

申办/合作机构

Otsuka Pharmaceutical Development & Commercialization, Inc.

NCT03896945 / Terminated临床2/3期

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Negative Symptoms of Schizophrenia

This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786, as compared with placebo, for the treatment of negative symptoms of schizophrenia.

开始日期2019-02-15

申办/合作机构

Otsuka Pharmaceutical Development & Commercialization, Inc.

100 项与 SCNA x σ1 receptor x P-gp x NMDA receptor 相关的临床结果

登录后查看更多信息

100 项与 SCNA x σ1 receptor x P-gp x NMDA receptor 相关的转化医学

登录后查看更多信息

0 项与 SCNA x σ1 receptor x P-gp x NMDA receptor 相关的专利（医药）

登录后查看更多信息